宁波美诺华药业股份有限公司 累积投票制实施细则 第一章 总 则 第一条 为维护中小股东的利益，规范公司法人治理结构，规范公司选举董 事行为，根据《上海证券交易所股票上市规则》《上市公司治理准则》和《宁波 美诺华药业股份有限公司章程》（以下简称"《公司章程》"），并结合公司具 体情况制定本细则。 第二条 本细则所称累积投票制主要适用于董事的选举，即：在选举两个以 上的董事席位时，股东拥有的投票权等于该股东持有股份数与待定董事总人数的 乘积。股东既可以用所有的投票权集中投票选举一位候选董事，也可以分散投票 数位候选董事，董事一般由获得投票数较多者当选。 第三条 本实施细则所称的"董事"包括独立董事和非独立董事。由职工代 表担任的董事由公司职工民主选举产生或更换，不适用于本实施细则的相关规定。 第四条 公司董事会、独立董事、符合条件的股东可以向公司股东征集其在 股东会上的投票权，征集人应在委托权限范围内,代表股东投票选举董事,详细规 定另行制定。 第五条 公司通过累积投票制选举产生的董事，其任期不实施交错任期制， 即届中因缺额而补选的董事任期为本届余任期限，不跨届任职。 第二章 累积投票制的投票原则 第六条 股东会 ...

宁波美诺华药业股份有限公司 《中华人民共和国证券法》 《上海证券交易所股票上市规则》等法律法规、规范性文件，以及《宁波美诺华 药业股份有限公司章程》 （以下简称《公司章程》）的有关规定，结合公司的实际 情况，制定本制度。 第二条 本制度适用于公司及公司的控股子公司（包括全资子公司及其他控 股子公司，下同）。公司为他人提供担保，包括为其控股子公司或者合并报表范 围内其他主体提供担保，适用本制度的规定。 第三条 本制度所称对外担保是指公司以自有资产或信用为其它单位或个人 提供的保证、资产抵押、质押以及其它担保事项，包括公司对子公司的担保。具 体种类包括借款担保、银行开立信用证和银行承兑汇票担保、开具保函的担保等。 第四条 公司控股子公司对于向公司合并报表范围之外的主体提供担保的， 应视同公司提供担保。其对外担保应执行本制度，并应获得公司董事会批准。公 司子公司在其董事会或股东会做出决议后应及时通知公司董事会秘书。 对外担保管理制度 第一章 总 则 第一条 为了规范宁波美诺华药业股份有限公司（以下简称"公司"）的对外 担保行为，防范对外担保风险，确保公司资产安全和保护投资者的合法权益，根 据《中华人民共和国民法典》 ...

《上海证券交易所股票上市规则》 宁波美诺华药业股份有限公司 董事会议事规则 第一章 总 则 第一条 为明确宁波美诺华药业股份有限公司（以下简称"公司"）董事会的职责权限， 规范董事会组织、董事行为及操作规则，充分发挥董事会的作用，督促董事正确行使其权利 并履行其义务, 完善公司的法人治理结构，根据《中华人民共和国公司法》、 《中华人民共和 国证券法》、 （以下简称《股票上市规则》）等法律法规、规 范性文件，以及《宁波美诺华药业股份有限公司章程》 （以下简称《公司章程》 ）的有关规定， 制定本规则，作为董事及董事会运作的行为准则。 第二章 董事会的组成和职权 第二条 公司董事会由 5 名董事组成，独立董事 2 名，设董事长 1 名。董事长和副董事 长由董事会以全体董事的过半数选举产生。 第三条 董事可以由高级管理人员兼任，但兼任高级管理人员职务的董事以及由职工代 表担任的董事，总计不得超过公司董事总数的 1/2。 第四条 董事会行使下列职权： （一）召集股东会，并向股东会报告工作； （二）执行股东会的决议； （三）决定公司的经营计划和投资方案； （四）制订公司的利润分配方案和弥补亏损方案； （五）制订公司增加或 ...

Core Viewpoint - The company has established a comprehensive system for managing public opinion to enhance its ability to respond to various types of public sentiment and protect investor rights [2][3]. Group 1: Definition and Classification of Public Sentiment - Public sentiment includes negative media coverage, rumors that may harm the company, information affecting investor decisions, and other events impacting stock prices [2]. - Public sentiment is classified into major public sentiment, which significantly affects the company's image and operations, and general public sentiment, which is less impactful [2]. Group 2: Organizational Structure and Responsibilities - The company has formed a Public Sentiment Management Working Group led by the chairman, with responsibilities including decision-making and coordinating responses to public sentiment [3][4]. - The Securities Affairs Department is responsible for monitoring and reporting significant public sentiment, ensuring timely communication with the board [4]. Group 3: Principles and Measures for Handling Public Sentiment - The company emphasizes quick response, coordinated communication, proactive engagement, and systematic operations in managing public sentiment [5][6]. - For major public sentiment, the working group will investigate the situation, communicate with media, and ensure transparent communication with investors [6]. Group 4: Reporting and Handling Procedures - The reporting process involves immediate notification to the board secretary upon detection of public sentiment, especially for major issues [5][6]. - General public sentiment can be handled flexibly by the board secretary and the Securities Affairs Department based on specific circumstances [6]. Group 5: Accountability and Legal Considerations - Employees and related personnel have confidentiality obligations regarding public sentiment information, with potential penalties for breaches [7]. - The company reserves the right to pursue legal action against media spreading false information that harms its reputation [7].

Core Points - The company is named Ningbo Meinuohua Pharmaceutical Co., Ltd., established as a joint-stock company in accordance with the Company Law of the People's Republic of China [1][2] - The registered capital of the company is RMB 219,822,861 [1] - The company was approved by the China Securities Regulatory Commission to issue 30 million shares to the public in 2017 and was listed on the Shanghai Stock Exchange [1][3] Chapter Summaries Chapter 1: General Provisions - The purpose of the articles is to protect the legal rights of the company, shareholders, employees, and creditors [1] - The company is a permanent joint-stock company [1] - The legal representative of the company is the chairman of the board [1] Chapter 2: Business Objectives and Scope - The company's business objective is to create a leading large-scale biopharmaceutical group with independent intellectual property rights and core competitiveness [1] - The business scope includes the production of tablets and capsules, sales of pharmaceutical raw materials, and research and development of pharmaceutical intermediates [1] Chapter 3: Shares - The total number of shares is 219,822,861, all of which are ordinary shares [3] - The company can increase registered capital through various methods, including issuing shares to unspecified objects or existing shareholders [3][4] - The company is prohibited from repurchasing its own shares except under specific circumstances [4] Chapter 4: Shareholders and Shareholder Meetings - Shareholders have rights to dividends, voting, and supervision of the company's operations [6] - The company must hold an annual general meeting within six months after the end of the previous fiscal year [10] - Shareholder meetings can be called by the board of directors or by shareholders holding more than 10% of the shares [12] Chapter 5: Proposals and Notifications for Shareholder Meetings - Proposals must fall within the authority of the shareholder meeting and be clearly defined [13] - Shareholders can propose temporary motions 10 days before the meeting [13] Chapter 6: Voting and Resolutions of Shareholder Meetings - Ordinary resolutions require a simple majority, while special resolutions require two-thirds of the votes [18] - The company must disclose the results of voting on significant matters affecting minority investors [19]

General Principles - The company establishes an external investment management system to enhance the management of external investments, standardize investment behavior, and improve investment efficiency [1][3] - The system outlines principles, decision-making procedures, approval authority, management, and post-investment evaluation [1][3] Investment Definition - External investment refers to profit-oriented or value-preserving investments made by the company, its controlling subsidiaries, or entities under its actual control, including equity investments in newly established enterprises, capital increases, and asset acquisitions [1][4] Investment Management Principles - Investments must align with national laws, regulations, and industry policies [3][4] - The investment management should adhere to the company's development strategy and not adversely affect its main business [4][5] - The principle of prioritizing benefits and controlling investment risks must be followed [4][5] Decision-Making and Approval Process - The company's board of directors and shareholders' meeting serve as the decision-making bodies for external investments, with no other departments or individuals authorized to make such decisions [3][4] - The board's strategic committee is responsible for pre-reviewing major investments and monitoring project execution [3][4] Approval Authority - Major investment matters require board approval and must be submitted to the shareholders' meeting if they meet specific thresholds, such as asset totals exceeding 50% of the company's audited total assets or profits exceeding 50% of the last audited net profit [5][6] - Investments that meet certain criteria, such as involving 10% of total assets or net assets, require board approval [6][7] Post-Investment Management - The company must strengthen post-investment management to ensure asset preservation and value increase [10][11] - Investment disposal processes must follow established approval procedures, and the company should ensure timely accounting treatment of investment disposals [10][11] Documentation and Compliance - All relevant documents, including meeting minutes and investment contracts, must be archived for future reference [11][12] - The system will take effect upon approval by the shareholders' meeting and will be interpreted by the board of directors [12]

Core Viewpoint - The document outlines the independent director system of Ningbo Meinuo Pharmaceutical Co., Ltd., emphasizing the importance of independent directors in corporate governance and their roles in protecting the interests of minority shareholders. Group 1: General Principles - The independent director system aims to enhance the corporate governance structure of the company and ensure compliance with relevant laws and regulations [1] - Independent directors are defined as those who do not hold any other positions in the company and have no direct or indirect interests that could affect their independent judgment [1] - The proportion of independent directors on the board must not be less than one-third, including at least one accounting professional [1][2] Group 2: Qualifications of Independent Directors - Independent directors must meet specific legal and regulatory qualifications, including having at least five years of relevant work experience [6] - Individuals with significant relationships with the company or its major shareholders are prohibited from serving as independent directors [3][4] Group 3: Responsibilities and Duties - Independent directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing professional advice to enhance decision-making [13] - They have the authority to independently hire intermediaries for audits or consultations and can propose the convening of temporary shareholder meetings [14] Group 4: Meeting Procedures - Independent directors must hold at least one special meeting annually, and meetings can be called at the request of two or more independent directors [15] - Decisions made in special meetings require the approval of a majority of attending independent directors [16] Group 5: Support and Compensation - The company is required to provide necessary working conditions and support for independent directors to fulfill their responsibilities [19] - Independent directors are entitled to compensation that corresponds to their responsibilities, which must be approved by the board and disclosed in the annual report [42]

Core Points - The article outlines the investor relations management system of Ningbo Meinuo Pharmaceutical Co., Ltd, emphasizing the principles of fairness, openness, and integrity in communication with investors [1][2] - The company establishes a structured approach to investor reception and promotion, detailing the responsibilities of the board secretary and the securities affairs department [1][2] Group 1: General Principles - The company aims to enhance investor relations management and improve corporate governance by adhering to principles such as fairness, honesty, confidentiality, and efficiency [1][2] - The company prohibits unauthorized personnel from representing the company in investor relations activities, ensuring that only trained individuals participate [2] Group 2: Reception and Promotion Content - The company targets various stakeholders for its reception and promotion activities, including securities analysts, institutional investors, major shareholders, and media personnel [2][3] - Multiple communication channels are utilized, including the company website, stock exchange platforms, and investor education bases, to facilitate engagement with investors [3][4] Group 3: Communication and Disclosure - The company is committed to maintaining transparency by not disclosing any undisclosed significant information during communications with investors [4][5] - A detailed record-keeping system is established for all investor interactions, including the documentation of discussions and materials provided [5][6] Group 4: Compliance and Accountability - The company mandates that all investor-related activities be documented and that any violations of the established protocols will result in accountability for the involved parties [6][6] - The board of directors is responsible for interpreting the investor relations management system, which will take effect upon approval [6][6]

转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 证券代码：603538 证券简称：美诺华 公告编号：2025-095 关于修订、制定公司部分管理制度的公告 根据《中华人民共和国公司法》 《中华人民共和国证券法》 引》等有关法律、法规和规范性文件的最新规定，结合公司实际经营管理情况， 董事会同意修订、制定公司部分管理制度。具体情况如下： 《上市公司章程指 序号 修订的管理制度名称 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波美诺华药业股份有限公司(以下简称"公司")于 2025 年 8 月 26 日召开 第五届董事会第十六次会议，审议通过了《关于修订、制定公司部分管理制度的 议案》。 序号 制定的管理制度名称 具体内容详见公司于上海证券交易所网（www.sse.com.cn）等指定信息披露 媒体同日披露的公司相关管理制度。 宁波美诺华药业股份有限公司 董事会 上述管理制度的修订、制定已经公司第五届董事会第十六次会议审议通过， 其中第 1—10 项、第 28 项制度尚需提交公司股东大会审议,其余制度 ...

Core Viewpoint - The document outlines the information disclosure management system of Ningbo Meinuo Pharmaceutical Co., Ltd, emphasizing the importance of accurate, timely, and fair disclosure of information that may impact stock trading prices [1][2]. Group 1: Information Disclosure Management - The company establishes a system to regulate the information disclosure behavior of its board members and senior management, ensuring compliance with relevant laws and regulations [1]. - Information that may affect stock trading prices includes periodic reports, temporary announcements, financial summaries, and other significant matters that are prepared but not yet disclosed [1][2]. - The board of directors leads the information disclosure work, with the board secretary responsible for handling external information publication [1][2]. Group 2: Confidentiality and Insider Information - Board members and senior management are required to maintain confidentiality regarding undisclosed significant information and are prohibited from leaking such information before it is publicly disclosed [2][3]. - There are strict rules against insider trading and market manipulation, with board members and senior management not allowed to disclose any undisclosed periodic reports or temporary announcements [2][3]. - The company has established a system for insider information knowledge, ensuring that those privy to undisclosed information adhere to confidentiality obligations [2][3]. Group 3: Approval and Reporting Process - Any external documents that need to be published must be submitted to the securities affairs department for review and approval by the board secretary before release [2][3]. - The company must refuse to submit annual statistical reports from external units that lack legal basis, while ensuring that any legally required submissions are documented and approved [3][4]. - External units or individuals are prohibited from disclosing any undisclosed significant information obtained through legal reporting requirements [4][5]. Group 4: Compliance and Accountability - The company mandates strict adherence to the information disclosure management system by all departments and subsidiaries, holding them accountable for any violations that result in economic losses [5]. - Any individual or entity that uses undisclosed information for trading or advising others to trade in the company's securities may face legal consequences [5]. - The document stipulates that in cases of conflict between this system and applicable laws or regulations, the latter will take precedence [5].